Loading
Ferroptosis and Cancer Prognosis · Journal article
Advanced Science · August 11, 2026
Raises a question worth testing. It does not answer one.
This is a mechanistic study proposing that AR-driven MTF1 lactylation buffers copper toxicity in castration-resistant prostate cancer, and that disrupting this pathway could trigger cuproptosis. The work identifies a potential therapeutic vulnerability but provides no clinical trial data, human outcome measures, or quantified effect sizes in patients.
Journal article. Castration-resistant prostate cancer (CRPC); likely cell culture and animal models based on abstract description.. Intervention: MTF1 disruption to collapse copper buffering system; AR activation; EP300-dependent lactylation..
Tumor copper levels positively correlate with androgen receptor (AR) activity. CRPC with hyperactivated AR exhibits pathological copper accumulation. AR activation enhances copper uptake while conferring tolerance to copper toxicity.
AR activation enhances copper uptake while conferring tolerance to copper toxicity.
This identifies a mechanistic basis for cuproptosis as a potential therapeutic strategy in CRPC, but the absence of quantified effect sizes, patient numbers, or clinical trial data means no immediate practice implications can be drawn. Further translational work and clinical validation would be required.
Mechanistic study in cell and animal models identifying a pathway by which AR-driven copper buffering might be exploited; lacks clinical trial data or human outcome evidence.
As stated by the source record.
This identifies a mechanistic basis for cuproptosis as a potential therapeutic strategy in CRPC, but the absence of quantified effect sizes, patient numbers, or clinical trial data means no immediate practice implications can be drawn. Further translational work and clinical validation would be required.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
ABSTRACT Inducing cuproptosis for cancer therapy currently relies on supraphysiological copper or copper ionophores. Although serum copper is elevated in patients with prostate cancer, whether this is sufficient to trigger physiological cuproptosis remains unclear. Here, we show that tumor copper levels positively correlate with androgen receptor (AR) activity, and castration‐resistant prostate cancer (CRPC) with hyperactivated AR exhibits pathological copper accumulation. AR activation enhances copper uptake while simultaneously conferring tolerance to copper toxicity, creating a buffered copper state. This adaptive response is mediated by metal‐responsive transcription factor 1 (MTF1), which is transcriptionally upregulated by AR and undergoes EP300‐dependent lactylation of lysine 218, promoting copper‐induced nuclear translocation. Nuclear MTF1 activates metallothioneins (MT1E, MT1F, and MT1M) that sequester cytosolic copper and restrict mitochondrial copper accumulation. Disrupting MTF1 collapses this buffering system, enabling endogenous copper to trigger cuproptosis and suppress CRPC growth. These findings identify cuproptosis as a therapeutically exploitable vulnerability in CRPC.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.